Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with bendamustine for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).

This is written in the approval document as:

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).

Citation

Brentuximab vedotin and Bendamustine Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6526/529_v2_Brentuximab_bendamustine.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) CD30 + Hodgkin Lymphoma Bendamustine, Brentuximab vedotin